News CHMP backs J&J's myeloma bispecific Tecvayli, ahead of US de... The EMA's human medicines committee has recommended approval of Johnson & Johnson's Tecvayli as a fourth-line therapy for multip
News BioMarin starts rebuilding after its downsizing spree BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
